Mutant Enzyme Allows Any Blood Type to be Changed into Universal Blood Type O

Imagine if a blood type can be changed to suit the recipient’s needs? Canadian scientists have created an enzyme that could change any blood group into the universal blood type O.

When you need an emergency blood transfusion, what happens if the hospital or blood bank doesn’t have your blood type? It has been an issue that researchers have been trying to resolve for decades.

Scientific world has been looking at using enzymes derived from bacteria to remove antigens from red blood cells to produce Type O blood group, which is a universal donor. However, those enzymes haven't been effective and since a huge amount of enzymes was required to make a difference, it was also considered impractical.

AIDS/HIV - Worldwide distribution and Risk of Transmission
AIDS/HIV risk associated with blood transfusion is very if blood is routinely screened by the blood test

Scientists at the Center for Blood Research Center of the University of British Columbia (UBC) say that they have found a possible solution to this issue. They have created an enzyme that could change any blood group into Type O.

The norm at present is that Type A blood group can only be used to treat A or AB people, and Type B can only be given to B or AB people. Type O is transfusion-friendly and can be given to anyone because it contains no A or B antigens. People with Type O group can donate to all blood groups but they can only receive from their own group.

According to the scientists, however, the new enzyme works by removing antigens from Type A and Type B blood, making it work like Type O. They used a new technology called directed evolution to create a mutant enzyme that's much more effective.

Blood Transfusion-Related Complication More Common Than Previously Thought
Two studies shed new light on the prevalence of transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO), the number one and two leading causes of blood transfusion-related deaths in the United States.

In their experiment, scientists inserted mutations into the bacterial gene that codes for the enzyme. Subsequently, they selected mutants that were particularly effective at removing the antigens. They did this for five generations and created an enzyme that was 170 times more efficient at antigen-clipping than its original predecessors.

David Kwan, the lead author of the study and a postdoctoral fellow at Department of Chemistry, UBC, said that the enzymes were able to snip off wide majority of the antigens in Type A and B blood.

Safer Blood Transfusion Symposium in India: Highlights
Making blood transfusion safer in India was the focus of the symposium on Sunday that had experts from Transfusion Medicine speaking on the event organized by Jeevan Blood Bank, Chennai, India.

“We produced a mutant enzyme that is very efficient at cutting off the sugars in A and B blood types, and also much more proficient at removing the subtypes of the A-antigen that the parent enzyme struggles with. The conversion process with very small amounts of enzyme is cheaper and less problematic when retrieving the enzyme (after the blood conversion). This process takes over a few hours. It could also be done in minutes using a lot of enzyme. Overall, the speed of this technology depends completely onhow much enzyme we use,” Kwan said.

Steve Withers, a professor in the Department of Chemistry, UBC, said that some more basic research and safety tests are required to substantiate these findings and bring this technology into everyday practice.

Treatment of Iron Deficiency Anemia - Oral Medications - Parenteral therapy - Blood transfusion - Treatment of related conditions
Oral medications, Parenteral therapy and blood transfusion are three options used to treat iron deficiency based on the severity of the condition.

“The concept is not new but until now, we needed so much of the enzyme to make it work that it was impractical. Now I’m confident that we can take this a whole lot further. However, it will take at-least 10 years to use the technology in clinical practice. Some more basic research is necessary and the process should go through the same safety and efficacy testing as any drug,” he said.

The enzyme would need to remove all of the antigens before it can be used in clinical settings because the immune system is highly sensitive to blood groups. Even a few incompatible antigens in a transfusion could activate an immune response and can be very harmful for patients.

The study was published in the Journal of the American Chemical Society. The study was supported by the Canadian Institutes of Health Research and Canadian Blood Services.

Source-Medindia